Study guide
3.4 Neurogenic Bladder, Bowel & Secondary Complications
ABPMR Physical Medicine and Rehabilitation Board Exam Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 ABPMR Part I Exam Overview & Format 1.2 Board Review Strategy & Content Blueprint Breakdown
2 Chapter 2: Musculoskeletal Medicine
2.1 Shoulder & Upper Extremity Diagnostics 2.2 Knee, Hip & Lower Extremity Conditions 2.3 Spine Pathology, Radiculopathy & Myelopathy 2.4 Inflammatory Arthritis, Tendinopathies & Concussion 2.5 Bone Health, Osteoporosis & Metabolic Bone Disease 2.6 Thoracic Outlet Syndrome & Peripheral Nerve Entrapment 2.7 Fracture Rehabilitation & Immobilization Complications 2.8 Overuse Tendinopathies & Regenerative Medicine 2.9 Gait Analysis & Abnormal Gait Patterns
3 Chapter 3: Spinal Cord Injury Rehabilitation
3.1 ASIA Examination & Impairment Scale 3.2 Spinal Cord Injury Syndromes 3.3 Autonomic Dysreflexia & Acute Complications 3.4 Neurogenic Bladder, Bowel & Secondary Complications
4 Chapter 4: Stroke & Neuromuscular Rehabilitation
4.1 Stroke Vascular Syndromes & Acute Assessment 4.2 Stroke Motor Recovery & Hemiplegic Complications 4.3 Spasticity Assessment & Multimodal Management 4.4 ALS, GBS, CIDP & Neuromuscular Disease Rehab 4.5 Multiple Sclerosis & Demyelinating Disease Rehabilitation 4.6 Parkinsonism, Movement Disorders & Functional Neurologic Disorder
5 Chapter 5: Electrodiagnostics (EMG/NCS)
5.1 Nerve Conduction Studies Principles & Physics 5.2 Needle Electromyography & MUAP Analysis 5.3 Mononeuropathies & Radiculopathy Patterns 5.4 Neuromuscular Junction Disorders & Myopathies
6 Chapter 6: Traumatic Brain Injury
6.1 TBI Severity Classification, Glasgow Coma Scale, and Pathophysiology 6.2 Rancho Los Amigos Levels of Cognitive Functioning and Disability Rating Scale 6.3 Neurobehavioral Sequelae and Agitation Management 6.4 Concussion Evaluation, Vestibular-Ocular Dysfunction, and Return-to-Play/Work Protocols
7 Chapter 7: Chronic Pain & Interventional Spine
7.1 Fluoroscopic Spine Interventions 7.2 Opioid Stewardship & Controlled Substance Compliance 7.3 Complex Regional Pain Syndrome, Fibromyalgia & Myofascial Pain 7.4 Spinal Cord Stimulation & Intrathecal Therapy
8 Chapter 8: Amputee Rehabilitation & Prosthetics
8.1 Amputation Surgical Levels & Medicare K-Levels 8.2 Socket Designs & Suspension Systems 8.3 Prosthetic Feet & Microprocessor Knee Mechanisms 8.4 Post-Amputation Care, Residual Limb & Phantom Pain
9 Chapter 9: Pediatric Rehabilitation
9.1 Cerebral Palsy Classification & GMFCS 9.2 Spina Bifida & Myelomeningocele Management 9.3 Muscular Dystrophies & Neuromuscular Disease in Children 9.4 Pediatric Brachial Plexopathy & Congenital Disorders
10 Chapter 10: Prosthetics, Orthotics & Assistive Technology
10.1 Lower Limb Orthoses — AFOs & KAFOs 10.2 Spinal & Upper Extremity Orthoses 10.3 Upper Limb Prosthetics — Body-Powered vs Myoelectric 10.4 Wheelchairs, Seating Systems & Pressure Mapping
11 Chapter 11: Medical Rehabilitation & Outcomes
11.1 Dysphagia Assessment & Management 11.2 Neurogenic Bladder & Bowel Management 11.3 Pressure Injuries & Wound Management 11.4 Outcome Measures & Medical Complications 11.5 Cancer Rehabilitation & Oncologic Rehabilitation 11.6 Burns, Endocrine/Metabolic & Medical Complications Rehabilitation
12 Chapter 12: Cardiopulmonary Rehabilitation
12.1 Cardiac Rehabilitation Phases & Metabolic Equivalents 12.2 Pulmonary Rehabilitation & COPD Management
13 Chapter 13: Foundational Rehabilitation Concepts
13.1 Kinesiology, Biomechanics & Functional Anatomy 13.2 Rehabilitation Pharmacology & Medication Management 13.3 Research Methodology, Biostatistics & Evidence-Based Practice 13.4 Nutrition, Metabolism & Energy Expenditure in Rehabilitation 13.5 Diagnostic Procedures: Imaging, MSK Ultrasound, Urodynamics & Neuropsych Assessment
3.4 Neurogenic Bladder, Bowel & Secondary Complications
Key Takeaways Explain This Topic AI
Suprasacral SCI (above T12) produces Upper Motor Neuron (UMN) detrusor hyperreflexia and Detrusor-Sphincter Dyssynergia (DSD), requiring Clean Intermittent Catheterization (CIC) and anticholinergics/beta-3 agonists to prevent high-pressure renal injury.
Sacral SCI (S2-S4) produces Lower Motor Neuron (LMN) areflexic bladder with high capacity and overflow incontinence, managed with scheduled CIC.
Neurogenic bowel is categorized into UMN spastic bowel (managed with suppositories and digital rectal stimulation) and LMN flaccid bowel (managed with manual evacuation and stool bulking).
Heterotopic Ossification (HO) presents with warm, swollen periarticular tissue (most commonly hips), diagnosed early by bone scan and elevated serum Alkaline Phosphatase, managed with indomethacin or bisphosphonates.
Pressure injuries are staged according to NPIAP criteria from Stage 1 (non-blanchable erythema) to Stage 4 (exposed bone/muscle), Unstageable (slough/eschar cover), and Deep Tissue Injury (persistent non-blanchable purple discoloration).
Last updated: July 2026
3.4 Neurogenic Bladder, Bowel & Secondary Complications
Long-term medical management in spinal cord injury (SCI) rehabilitation focuses on preventing secondary complications, preserving organ function, and maximizing quality of life. Neurogenic bladder, neurogenic bowel, heterotopic ossification, and pressure injuries represent core competencies tested extensively on the ABPMR board examination.
Neurogenic Bladder Dysfunction
The neural control of lower urinary tract function involves complex integration between the frontal cortex, pontine micturition center (PMC), thoracolumbar sympathetic center (T11-L2), and sacral parasympathetic center (S2-S4). Spinal cord injury disrupts these ascending and descending pathways.
Upper Motor Neuron (UMN) Bladder (Suprasacral Lesion, Above T12)
Pathophysiology : Disruption of pathways between PMC and sacral cord. Results in Neurogenic Detrusor Overactivity (NDO) (involuntary detrusor contractions) and Detrusor-Sphincter Dyssynergia (DSD) (simultaneous involuntary contraction of the urethral sphincter during detrusor contraction).
Complications : High intravesical storage pressures (>40 cm H2O), vesicoureteral reflux (VUR), hydronephrosis, autonomic dysreflexia, and renal failure.
Management Goals : Maintain low-pressure storage (<40 cm H2O), maintain catheterized volumes <400-500 mL, ensure low residual volumes, and prevent upper tract damage.
Primary Treatment :
Clean Intermittent Catheterization (CIC) : Gold standard method of bladder emptying (every 4-6 hours).
Anticholinergic Medications : Oxybutynin, solifenacin, or trospium to inhibit detrusor overactivity.
Beta-3 Adrenergic Agonists : Mirabegron or vibegron (alternative/additive relaxation of detrusor without anticholinergic side effects).
Intravesical Botulinum Toxin Type A : Injected into detrusor muscle for refractory NDO.
Lower Motor Neuron (LMN) Bladder (Sacral/Infrasacral Lesion, S2-S4 / Cauda Equina)
Pathophysiology : Direct destruction of sacral micturition center or sacral nerve roots. Results in an areflexic, hypotonic bladder with loss of detrusor contractility and variable sphincter tone.
Complications : Large capacity bladder, urinary retention, overflow incontinence, and recurrent UTIs.
Management : Scheduled CIC. Crede maneuver (manual abdominal compression) or Valsalva maneuver are generally discouraged due to risk of inguinal hernia, hemorrhoids, and high urethral resistance.
Neurogenic Bowel Management
Gastrointestinal motility and defecation reflexes depend on extrinsic innervation from the vagus nerve and sacral parasympathetic roots (S2-S4).
- Feature UMN Bowel (Hyperreflexic / Spastic) LMN Bowel (Areflexic / Flaccid)
- Lesion Location Above S2 segment (T12 and above) S2-S4 segments, conus, or cauda equina
Pathophysiology Intact spinal reflex arc; puborectalis & external anal sphincter spastic Disrupted spinal reflex arc; anal sphincter flaccid & lax
Clinical Stool Pattern Stool retention; constipation Fecal incontinence; stool impaction
Primary Management Daily or QOD bowel program: High fiber, oral stool softener (docusate), contact irritant suppository (bisacodyl) followed by digital rectal stimulation Daily or BID manual evacuation; stool bulking agents (psyllium); avoid suppositories (no reflex contraction)
Heterotopic Ossification (HO)
Heterotopic Ossification (HO) is the formation of true mature lamellar bone in periarticular soft tissue surrounding major joints below the level of spinal injury. It occurs in 20-30% of SCI patients.
Clinical Presentation & Localization
Most Common Sites : Hip (70-80%, anterior > posterior) > Knee > Elbow > Shoulder. HO never occurs within the joint space itself (it is extra-articular).
Signs & Symptoms : Decreased joint range of motion (ROM), warmth, swelling, erythema, localized tenderness, low-grade fever, and spasticity. Can trigger Autonomic Dysreflexia.
Diagnostics
Triple-Phase Bone Scan (Tc-99m MDP) : Most sensitive test for early diagnosis (positive within 2 weeks of onset, long before X-ray changes appear).
Serum Alkaline Phosphatase (ALP) : Rises significantly during active osteoblast activity (peaks at 6-10 weeks).
Plain Radiographs : Show mature bone calcification 4-6 weeks after onset.
Management
Pharmacotherapy : Indomethacin (75 mg daily) or Bisphosphonates (Etidronate 20 mg/kg/day or IV Zoledronic Acid) to inhibit osteoid mineralization during the acute active phase.
Physical Therapy : Gentle maintaining ROM exercises to preserve function (avoid aggressive forced ROM which may exacerbate microtrauma).
Surgical Excision : Reserved for severe functional limitation or ankylosis; performed only after HO maturity (typically 12 to 18 months, confirmed by normal ALP and cold bone scan).
Pressure Injuries (NPIAP Staging System)
Pressure injuries result from sustained pressure, shear, and friction over bony prominences (ischial tuberosity > trochanter > sacrum > calcaneus).
NPIAP Stage Clinical & Anatomical Description
Stage 1 Intact skin with non-blanchable erythema of a localized area. Darkly pigmented skin may not have visible blanching; color may differ from surrounding area.
Stage 2 Partial-thickness skin loss with exposed dermis. Wound bed is viable, pink/red, moist. Includes intact or ruptured serum-filled blisters. (No adipose tissue visible).
Stage 3 Full-thickness skin loss in which subcutaneous fat is visible . Granulation tissue and epibole (rolled edges) are often present. Bone, tendon, muscle, or cartilage are NOT exposed.
Stage 4 Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone . Slough and eschar may be visible.
Unstageable Full-thickness skin and tissue loss in which the extent of tissue damage within the ulcer cannot be confirmed because it is covered by slough or eschar .
Deep Tissue Injury (DTI) Intact or non-intact skin with localized area of persistent non-blanchable deep red, maroon, or purple discoloration , or epidermal separation revealing a dark wound bed or blood-filled blister.